AstraZeneca/Pozen file Vimovo in the EU
This article was originally published in Scrip
Executive Summary
AstraZeneca and Pozen Pharmaceuticals have submitted Vimovo (enteric-coated naproxen plus immediate release esomeprazole magnesium; formerly known as PN 400) for the treatment of osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing spondylitis (AS) in patients who are at risk of developing NSAID-associated ulcers.